Guiqi Rukang Powder, when specified for direct-compression veterinary tablet manufacture, requires a pre-formulation screen for loss on drying, angle of repose, bulk density, tapped density, and compressibility before the blend is committed to a rotary tablet press. On a production-scale rotary press equipped with a forced feeder and 10 mm round flat-faced bevelled punches, a representative direct-compression run uses a 10–15 kg batch blended for 15–20 min at 8–12 rpm in a V-blender with microcrystalline cellulose at 15–30% w/w, dibasic calcium phosphate anhydrous at 10–20% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. Tablet weight uniformity is monitored against USP <905>, with individual tablet weight acceptance limits of ± 3% and mean weight limits of ± 1.5%, while friability is controlled below 1.0% according to USP <1216>. If the certificate of analysis declares polysaccharide, saponin, or astragaloside-class marker fractions, quantification should use a validated HPLC method transferred under Chinese Veterinary Pharmacopoeia general guidance or Ph. Eur. 2.2.29; published data for the exact compression profile of this named botanical API are limited, so a 5 kg feasibility batch is the minimum data-bearing step before commercial scale-up. The terminal product is a film-coated oral tablet intended for individual dosing in dairy cows or sows, coated with a hydroxypropyl methylcellulose system to 2–3% weight gain in a perforated pan coater at 55–65°C inlet air temperature, 2–6 rpm pan speed, and 4–8 g/min spray rate to reduce moisture uptake and mask bitter botanical mouth feel.

Why Does Injectable Use Require a Separate Particle Engineering Strategy?

Injectable solution manufacture from a botanical powder API is constrained less by chemical potency than by the particulate, endotoxin, and heat-degradation interfaces that do not exist in oral solid dosage forms. When an injectable grade is requested, the raw powder must first be dispersed in water for injection complying with Ph. Eur. 0169, then clarified through a sequence of depth filtration, 0.45 µm membrane prefiltration, and 0.22 µm sterilizing-grade PVDF filtration, because residual insoluble plant cell debris can exceed the light obscuration limits of USP <788> for particles ≥ 10 µm and ≥ 25 µm per container. Endotoxin control is a separate critical threshold: the finished solution should be evaluated by the limulus amoebocyte lysate method under Ph. Eur. 2.6.14, with an acceptance criterion derived from the intended dose in cattle or sows rather than a universal herbal-powder limit. Terminal moist-heat sterilization at 121°C for 15 min is often unsuitable for polyphenolic and flavonoid fractions, so the production line may require aseptic filling through a single-use fluid path on a peristaltic pump-equipped vial line with 10–20 mL moulded glass vials, in-process hold time not exceeding 4 h at 15–25°C, and post-fill sterility testing under Ph. Eur. 2.6.1. Osmolality should be adjusted with sodium chloride or glycerol to 280–320 mOsm/kg, and pH should be maintained in the 5.5–7.0 window after accelerated stability screening because saponin-rich fractions may form pH-dependent haze at acidic endpoints. The terminal product is a sterile injectable solution or, if insoluble particulates cannot be economically removed, a sterile suspension requiring a particle-size reduction step to D90 ≤ 10 µm by wet milling before aseptic filling. Elemental impurity and residual solvent assessments should be aligned with VICH GL18 and ICH Q3D-derived risk assessment only when the API manufacturing route introduces extraction solvents or metal catalysts.

Hard capsule filling of this API is governed more by powder-bed rheology under a dosing disc than by the chemical stability of the botanical fractions themselves. On an intermittent-motion capsule machine operating at 60,000–100,000 capsules/h with size 0 or 00 hard gelatin or HPMC shells, the preblend must exhibit a flow function coefficient measured by ring shear testing sufficient to avoid ratholing in the feed hopper. Typical fill formulations use lactose monohydrate at 40–60% w/w, microcrystalline cellulose at 20–35% w/w, sodium starch glycolate at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w, with the lubricant added only during the final 3–5 min of blending to limit over-lubrication and delayed dissolution. The powder blend moisture should be held at ≤ 5.0% w/w and the processing suite at ≤ 45% RH to prevent capsule shell deformation, bridging, or brittle shell cracking observed on high-speed capsule lines. In-process control uses gravimetric fill weight verification at 15–20 min intervals, with acceptance limits aligned to USP <905>, and aerobic microbial limits assigned under Ph. Eur. 2.6.13 unless a tighter specification is justified for immunocompromised or neonatal animals. The terminal product is an immediate-release hard capsule for once-daily oral administration, typically in pigs or pre-ruminant calves, where individual dosing accuracy, masking of plant-derived bitterness, and protection of hygroscopic fractions from ambient humidity are the primary performance targets. Published data on the capsule fill weight stability of this specific botanical mixture are limited, so a pilot run of 20,000–50,000 capsules with full weight, disintegration, and moisture mapping is the objective minimum before transfer to commercial batch release.

Drench Solutions Routed Through Low-pH Vehicles Can Destabilise Polyphenolic Fractions

The development of an oral drench solution from Guiqi Rukang Powder introduces a preservative-versus-pH conflict that is absent in solid dosage forms. Potassium sorbate at 0.1–0.2% w/v and sodium benzoate at 0.1% w/v are effective only below approximately pH 4.5, yet polyphenolic and saponin fractions in botanical extracts frequently show visible haze, colour shift, or precipitate formation at acidic endpoints below pH 5.0. A robust drench formulation therefore requires a pH-stat stability screen from pH 4.0 to pH 7.0 in citric acid–phosphate buffers, with turbidity measured by nephelometry and marker content measured by HPLC after 7 and 14 days at 40°C ± 2°C. The compounding vessel should be a jacketed stainless steel tank with bottom-mounted high-shear disperser operated at 1,500–3,000 rpm for 10–20 min, followed by a cooling phase to 20–25°C before final volume adjustment. If a fully dissolved drench is not attainable, a suspension drench with xanthan gum at 0.2–0.4% w/v and microcrystalline cellulose co-processed with carboxymethylcellulose at 0.5–1.0% w/v provides a controlled sedimentation ratio above 0.9 after 24 h while maintaining pourability through a 30–60 mL dosing syringe. Preservative efficacy testing under Ph. Eur. 5.1.3 must be repeated after any pH or excipient change because plant-derived components may sequester preservatives through micellar or polyphenolic association. The terminal product is an oral drench or suspension packaged in amber HDPE containers with a recommended discard period after first opening, typically 28 days, supported by in-use stability data. Residual solvent analysis under VICH GL18 applies if ethanol, methanol, or acetone was used in API extraction or granulation upstream.

When the API Is Incorporated into a Granulated Premix, Binder Selection Overrides Raw Powder Flow

A granulated premix line for this botanical API changes the primary processing risk from powder segregation to wet-mass rheology and drying uniformity. In a high-shear mixer with a main impeller speed of 150–300 rpm and chopper speed of 1,500–3,000 rpm, the dry blend is pre-mixed for 5–10 min, then granulated with a binder solution of povidone K-30 at 2–5% w/w or pregelatinised starch at 5–10% w/w, added over 3–5 min to avoid overwetting the polysaccharide-rich fractions. The wet mass is transferred to a fluid-bed dryer with inlet air at 60–70°C and dried to a target loss on drying of 2.0–3.5% w/w, then milled through a 1.0 mm screen to yield granules with D50 between 150 µm and 250 µm. Overdrying below 1.5% w/w can cause friable granules and increased dust, while residual moisture above 4.0% w/w can accelerate microbial growth and caking in multi-active premix blends. The terminal granulated premix is filled into multi-layer paper sacks with an inner polyethylene liner, and homogeneity is verified by assay of a tracer or marker fraction at 10 sampling points according to documented sampling plans, with a coefficient of variation not exceeding 5% for the active marker. The granulated form is appropriate when the API is subsequently mixed with minerals, vitamins, or direct-fed microbials, because granule density and particle-size distribution can be matched to the other components to reduce segregation in auger feeding systems.

In medicated feed premix production for group medication, the key compliance driver is not tablet-content uniformity but batch-to-batch carryover and cross-contamination control in the mixer and downstream conveying line. A horizontal ribbon mixer with a working volume of 0.5–2.0 m³ is charged with a carrier such as wheat middlings or rice hulls at 60–90% w/w, vegetable oil or mineral oil binder at 0.5–1.0% w/w, and the botanical API at a ratio defined by the intended in-feed inclusion, followed by 10–15 min of mixing after the final component addition. Homogeneity is measured by salt tracer or ferric oxide tracer studies with a coefficient of variation not exceeding 10% at 10 sampling points, because the dusty, low-density botanical powder can otherwise segregate in the auger or pneumatic transfer line after discharge. Carryover validation should follow the residue-monitoring framework of EU Regulation 2019/4 on medicated feed, with flush batches or sequential production scheduling applied when the same line processes non-target species feed. Microbial quality of the finished premix should include absence of Salmonella in 25 g under ISO 6579-1:2017 and total aerobic count under ISO 4833-1:2013, with additional mould and yeast limits when the premix includes direct-fed microbials or organic carriers. The terminal premix is a free-flowing meal intended for incorporation into total mixed rations at a fixed grams-per-head daily dose, with the concentration adjusted so that the final feed contains the label-claim amount after dilution and mixing in the farm wagon. Published data on the aerodynamic dust potential of this specific API during transfer are limited; therefore, a dust suppression step such as oil binder addition or agglomeration should be validated on the actual production line rather than assumed from laboratory powder-flow tests.

Powder Top-Dress Uniformity and Feed Refusal Risk

Powder top-dress application of the undiluted API presents a narrow processing window between under-dispersion into the feed and palatability-driven refusal. When a 0.5–2.0 kg/tonne inclusion is dispersed onto a total mixed ration, the powder must be pre-blended with a free-flowing carrier at 1:10 to 1:20 before field application, otherwise segregation and dusting produce uneven intake across a pen. The preferred field equipment is a calibrated broadcast spreader or rotary top-dress applicator with a discharge rate verified at ± 5% of the target dose, and the carrier system should have a particle size within 100 µm of the ration components to reduce electrostatic adhesion to mixer surfaces. Feed refusal is the primary biological failure mode because bitter saponin and polyphenol fractions may reduce dry matter intake in high-producing dairy cows; a short-term acceptance trial over 5–7 days using the exact ration composition is more informative than a laboratory palatability panel. Terminal use is the direct application to individual sick pens or fresh-cow groups, where daily dose documentation and withdrawal period management follow the veterinary prescription and local regulatory requirements for botanical feed additives. No additional granulation, compression, or sterilisation is applied in this route, so the microbial and heavy metal profile of the starting API transfers directly to the feed, and each batch must conform to the same identity and purity specification required for the tableted or premix-grade material.